Cancer of lung is the most widespread cause of cancer death in the world. In the UK, approximately 100 people are diagnosed with the cancer on a daily basis, and roughly 1 in 5 of them will have small cell lung cancer, for which the rate of survival is very low: simply 3 per cent of patients with it are expected to live more than 5 years following diagnosis.
Chemotherapy applies drugs to kill cancer cells. One or more drugs of chemotherapy might be administered by means of a vein in your arm or taken orally. A combination of drugs typically is provided in a series of treatments over a period of weeks or months.
Chemotherapy could be applied as a first line treatment for lung cancer or as added treatment following surgery. In a number of cases, chemotherapy could be utilized to reduce side effects of your cancer.
Iressa (gefitinib) is an innovative new type of anti-cancer drug for people with the most common type of cancer of lung. It is unlike all prior chemotherapy. That is, Iressa works by distinctively blocking cellular enzymes that stimulate cell enlargement.
The Food and Drug Administration (FDA) announced the approval of Iressa (gefitinib) tablets as a sole agent treatment for patients with advanced non-small cell lung cancer. Iressa is being approved as a treatment for patients whose cancer has maintained to progress despite treatment with platinum-based and docetaxel chemotherapy, two drugs that are presently the standard of care in this disease.
The lung cancer drug Iressa has had noticeably positive effects for a number of the people who take it. Their tumors get smaller by more than 50 percent, and they live months and sometimes years longer than expected.
Iressa and drugs like Gleevac and Tarceva are part of a fairly new class of drugs. Different from standard chemotherapy drugs, the new class specifically targets a gene in tumors named the epidermal growth factor receptor. This receptor assists tumors spread and grow, and these drugs obstruct this receptor.